[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Faming Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100549669","effect-of-antibiotic-pretreatment-on-the-efficacy-of-wmt-in-the-treatment-of-irritable-bowel-syndrome-100549669",false,"NCT06437041","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome in Adults: a Multi-center, Randomized, Placebo-controlledClinical Study","Inclusion Criteria:\n\n1. Voluntarily signed the informed consent, age 18 years old or more, men and women all can;\n2. According to the Roman IV standard diagnosis of IBS: recurrent abdominal pain or discomfort, weekly attacks within the past 3 months at least 3 d, accompanied by the following two and two or more:\n\n(1) associated with defecation; (2) changes in defecation frequency; (3) changes in stool characteristics (appearance).\n\nThe following symptoms were not included in the diagnostic criteria but supported the diagnosis: (1) abnormal bowel frequency: bowel movements less than 3 times per week or more than 3 times per day; (2) the excrement characters and abnormal: dry bulb dung or hard dung, or paste dung\u002Fdilute waste water; (3) bowel effort; (4) Defecation urgency, endless defecation, mucus excretion and abdominal distension.\n\nDiagnostic considerations: (1) Diagnosis should be based on the exclusion of organic diseases; (2) the intestinal symptoms of irritable bowel syndrome has certain characteristics, such as abdominal pain or discomfort with bowel movements, this group of symptoms is different from the other functional bowel disease, such as functional constipation, functional diarrhea, functional abdominal pain). (3) Irritable bowel syndrome often coexists with other functional gastrointestinal disorders.\n\n3\\. The subjects or their legal representatives gave informed consent, fully understood the purpose of the study, were able to communicate well with the researchers, and understood and complied with the requirements of the study.\n\nExclusion Criteria:\n\n* Subjects meeting any of the following exclusion criteria must be excluded from the study:\n\n  1. The patient was accompanied by other mental disorders besides anxiety and depression.\n  2. Combined with the results of colonoscopy within the past 24 months, the patient has an organic lesion of the digestive tract (e.g., tumor, inflammation, anal fissure, Crohn's disease, ulcerative colitis, intestinal adhesion, intestinal tuberculosis, etc.).\n  3. Has a history of major surgery within 3 months or a history of severetrauma, and recovery is not completely;\n\n  6\\. There are contraindications to colonic transendoscopic intestinal tubeimplantation, such as severe intestinal stenosis, obstruction, deep ulcer,and high risk of operation perforation; Severe ulcers or a large numberof pseudopolyps exist in the fixed area of titanium clips, which are notsuitable for fixation. The subjects' behavior was seriously uncontrolled.\n\n  7\\. Any of the following abnormalities in cardiac function and performance:a. According to the New York Heart Association (NYHA) cardiacfunction classification, cardiac function grade # or above;b. new onset myocardial infarction or unstable angina pectoriswithin 6 months;c. ECG showed QTc prolongation (QTc≥ 450ms in men and≥470ms in women);d. Drug-refractory atrial arrhythmias and drug-refractory ventriculararrhythmias (including grade 2 or higher atrioventricular block).\n\n  8\\. Patients with poor lung function that is considered by the investigatorto have an impact on the study treatment, such as patients with acuteexacerbation of COPD or patients requiring long-term use of oral orintravenous steroids for control (except inhalers\u002Fsprays); 9. No control autoimmune disease and\u002For need long-term use of hormone(except local external use sex); 10. Patients with metabolic diseases and poorly controlled by drugs(such as thyroid dysfunction), or patients with metabolic diseases accompanied by gastrointestinal function complications (such as gastrointestinal autonomic nerve dysfunction, diabetic gastroparesis,etc.) 11. Suffering from reproductive system diseases (including but not limited toovarian cysts, endometriosis, primary dysmenorrhea, etc.) that may lead to abdominal pain; 12. Significant laboratory abnormalities that, in the judgment of theinvestigator, may affect the safety of the subjects or the completion ofthe clinical study, including:A) the hemoglobin \\\u003C 100 g\u002FL; B) Serum creatinine ≥1.5 times theupper limit of normal (ULN) C) abnormal liver function, defined asAST\\>1.5×ULN and\u002For ALT\\>1.5×ULN and\u002For total bilirubin \\>1.5×ULN;D) blood clotting function: PLT acuities were 80 x 109 \u002F L, APTT \\> 1.5 xULN, PT \\> 1.5 x ULN, INR \\> 1.5 x ULN; E) abnormal results or defecateoccult blood stool and has prompted the clinical significance of thegastrointestinal tract.\n\n  13\\. Have active hepatitis (requiring or taking long-term treatment), HIV, oractive tuberculosis; 14. A history of drug or alcohol abuse (i.e., drinking more than 14 servings per week of beer, 45 mL of 40% spirits, or 150 mL of wine) or substance abuse; 15. The known allergic to research similar drugs, drugs or accessories; 16. Use of anti-infective drugs (antibiotics, antifungal, antiviral) within 14days before enrollment, or need anti-infective treatment at enrollmentevaluation; 17. Drugs and supplements that affect gastrointestinal motility and functioncannot be stopped during the study, including but not limited to:antibiotics such as erythromycin; Drugs that modulate the intestinal microecology, such as probiotics such as Bifidobacterium; Theparasympathetic nerve inhibitors, some scopolamine and atropine,belladonna, etc; Muscle relaxants, such as succinylcholine; Opioid preparations; Drugs thatinhibit gastric acid secretion; 18. Pregnant or lactating women, or refusing to use an effectivecontraceptive method within 3 months after the last dose of treatment; 19. 3 months prior to dosing involved in drug interventional clinical trials; 20. Suffering from malignant tumors;21. There were other circumstances that the investigator consideredinappropriate for participatin","ALL","18 Years",{"count":19,"type":20},96,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a randomized controlled trial to explore the efficacy of antibiotic pretreatment on the efficacy of WMT in the treatment of Irritable bowel syndrome in adults: a multi-center, randomized, placebo-controlled clinical study",[26],"Irritable Bowel Syndrome",[28,29,30,31,32],"Irritable bowel syndrome","washed microbiota transplantation","antibiotic pretreatment","randomized controlled trial","transendoscopic enteral tube","NOT_YET_RECRUITING","2024-05-24",{"date":36,"type":37},"2024-05-31","ACTUAL",{"date":39,"type":20},"2024-06",{"date":41,"type":20},"2030-03-31",{"name":43,"class":44},"Faming Zhang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":45},"100548966","effect-of-antibiotic-pretreatment-on-the-efficacy-of-wmt-in-the-treatment-of-chronic-constipation-100548966","NCT06427863","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation","Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation in Adults: a Multi-center, Randomized, Placebo-controlled Clinical Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Male and female, aged ≥18 years old, provided written informed consent;\n2. Subjects diagnosed with chronic constipation, with a duration of at least 6 months, and with the following conditions:\n\n1\\) spontaneous bowel movement frequency \\\u003C3 times\u002Fweek (spontaneous bowel movement was defined as spontaneous bowel movement without rescue laxatives or manual assistance); 2) waste hard: at least 25% of defecation in Bristol stool traits scale type 1 or 2.\n\n3\\. The subjects or their legal representatives gave informed consent, fully understood the purpose of the study, were able to communicate well with the researchers, and understood and complied with the requirements of the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded fromthe study:\n\n1. Presence of outlet obstruction and constipation, such as rectal mucosal prolapse\n2. Combined with the results of colonoscopy in the past 24 months, those with intestinal stenosis caused by organic lesions of the digestive tract (such as tumor, inflammation, anal fissure, Crohn's disease, ulcerative colitis, intestinal adhesion, intestinal tuberculosis, etc.) and constipation;\n3. Constipation caused by other systemic diseases involving the digestive tract, such as nervous system diseases (such as Parkinson's disease, spinal cord injury, multiple sclerosis, etc.), muscle diseases (such as amyloidosis, dermatomyositis, etc.), mental disorders (such as depression, etc.), metabolic and endocrine disorders (such as diabetes, hypothyroidism, etc.) or opioids, etc.\n4. Has a history of abdominal pelvic surgery, but after cystic resection, cesarean section, does not appear after appendectomy postoperative intestinal complications, and intestinal polyps except after treatment;\n5. Has a history of major surgery within 3 months or a history of severe trauma, and recovery is not completely;\n6. There are contraindications to colonic transendoscopic intestinal tube implantation, such as severe intestinal stenosis, obstruction, deep ulcer, and high risk of operation perforation; Severe ulcers or a large number of pseudopolyps exist in the fixed area of titanium clips, which are not suitable for fixation. The subjects' behavior was seriously uncontrolled.\n7. Any of the following abnormalities in cardiac function and performance:\n\n   1. According to the New York Heart Association (NYHA) cardiac function classification, cardiac function grade Ⅲ or above;\n   2. new onset myocardial infarction or unstable angina pectoris within 6 months;\n   3. ECG showed QTc prolongation (QTc≥ 450ms in men and ≥470ms in women);\n   4. Drug-refractory atrial arrhythmias and drug-refractory ventricular arrhythmias (including grade 2 or higher atrioventricular block).\n8. Patients with poor lung function that is considered by the investigator to have an impact on the study treatment, such as patients with acute exacerbation of COPD or patients requiring long-term use of oral or intravenous steroids for control (except inhalers\u002Fsprays);\n9. No control autoimmune disease and\u002For need long-term use of hormone (except local external use sex);\n10. Patients with metabolic diseases and poorly controlled by drugs (such as thyroid dysfunction), or patients with metabolic diseases accompanied by gastrointestinal function complications (such as gastrointestinal autonomic nerve dysfunction, diabetic gastroparesis, etc.);\n11. Suffering from reproductive system diseases (including but not limited to ovarian cysts, endometriosis, primary dysmenorrhea, etc.) that may lead to abdominal pain;\n12. Significant laboratory abnormalities that, in the judgment of the investigator, may affect the safety of the subjects or the completion of the clinical study, including:\n\n    A) the hemoglobin \\\u003C 100 g\u002FL; B) Serum creatinine ≥1.5 times the upper limit of normal (ULN) C) abnormal liver function, defined as AST\\>1.5×ULN and\u002For ALT\\>1.5×ULN and\u002For total bilirubin \\>1.5×ULN; D) blood clotting function: PLT acuities were 80 x 109 \u002F L, APTT \\> 1.5 x ULN, PT \\> 1.5 x ULN, INR \\> 1.5 x ULN; E) abnormal results or defecate occult blood stool and has prompted the clinical significance of the gastrointestinal tract.\n13. Have active hepatitis (requiring or taking long-term treatment), HIV, or active tuberculosis;\n14. A history of drug or alcohol abuse (i.e., drinking more than 14 servings per week of beer, 45 mL of 40% spirits, or 150 mL of wine) or substance abuse;\n15. The known allergic to research similar drugs, drugs or accessories;\n16. Use of anti-infective drugs (antibiotics, antifungal, antiviral) within 14 days before enrollment, or need anti-infective treatment at enrollment evaluation;\n17. Drugs and supplements that affect gastrointestinal motility and function cannot be stopped during the study, including but not limited to: antibiotics such as erythromycin; Drugs that modulate the intestinal microecology, such as probiotics such as Bifidobacterium; The parasympathetic nerve inhibitors, some scopolamine and atropine, belladonna, etc; Muscle relaxants, such as succinylcholine; Antidiarrheal agents such as loperamide, smecta; Opioid preparations; Drugs that inhibit gastric acid secretion;\n18. Pregnant or lactating women, or refusing to use an effective contraceptive method within 3 months after the last dose of treatment;\n19. 3 months prior to dosing involved in drug interventional clinical trials;\n20. Suffering from malignant tumors;\n21. There were other circumstances that the investigator considered inappropriate for participating in the study.",{"count":19,"type":20},[23],"This is a randomized controlled trial to explore the efficacy of antibiotic pretreatment on the efficacy of WMT in the treatment of chronic constipation in adults: a multi-center, randomized, placebo-controlled clinical study",[57],"Chronic Constipation",[59,29,30,31,32],"chronic constipation","2024-05-20",{"date":34,"type":37},{"date":39,"type":20},{"date":64,"type":20},"2029-12-31",{"name":43,"class":44},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":45},"100375488","caes-for-internal-hemorrhoids-and-rectal-prolapse-100375488","NCT04169152","CAES for Internal Hemorrhoids and Rectal Prolapse","Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse: a National Multi-centre Prospective Cohort Study","Inclusion Criteria:\n\n1. Grade I-III internal hemorrhoids (with or without external hemorrhoids) or\u002Fand recal prolapse.\n2. Patients with bowel preparation.\n\nExclusion Criteria:\n\n1. History of anoscopic\u002Fendoscopic sclerotherapy.\n2. Acute thrombotic hemorrhoids or grade IV internal hemorrhoids.\n3. Anal stenosis, perianal and perirectal abscess, anal fissure, fistula, fecal incontinence and other severe complications (such as severe anal pain).\n4. Inflammatory bowel disease.\n5. Full-thickness rectal prolapse through the anus.\n6. Acute diarrhea in the past 24 hours.\n7. Hypertensive with uncontrolled blood pressure.\n8. Cerebrovascular accident.\n9. Blood coagulation dysfunction.\n10. Pregnant women.\n11. Mental disorders.\n12. Decompensated cirrhosis.",{"count":74,"type":20},10000,"OBSERVATIONAL","Cap-assisted endoscopic sclerotherapy (CAES) is a new interventional therapy for internal hemorrhoids and rectal prolapse under colonoscopy. However, the long-term efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse are still not clear due to the lack of large sample studies. Therefore, a nationwide multi-center, large sample, prospective and cohort study was designed to evaluate the efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse, to provide reliable evidence for popularization of this minimally invasive technology.",[78,79],"Internal Hemorrhoid","Rectal Prolapse",[81,78,79],"Cap-assisted endoscopic sclerotherapy","RECRUITING","2024-04-01",{"date":85,"type":37},"2024-04-02",{"date":87,"type":37},"2019-12-30",{"date":89,"type":20},"2028-06-30",{"name":43,"class":44},""]